XtalPi and DoveTree Ink $6 Billion AI-Powered Drug Discovery Deal
XtalPi teams up with DoveTree in a $6 billion AI-powered drug discovery partnership to develop new small molecules and antibodies across major disease areas.
Shenzhen-based XtalPi, founded by MIT physicists, leverages its quantum physics-powered AI and robotics platform to accelerate drug discovery. The company has partnered with Harvard biotech leader Gregory Verdine’s DoveTree to develop small molecule and antibody drugs targeting cancer, autoimmune, neurological, and metabolic diseases.
The deal includes an upfront $51 million payment, followed by $49 million within months, plus potential milestone payments of up to $6 billion and tiered royalties. This collaboration underscores how advanced AI combined with expert drug development is reshaping pharmaceutical R&D by boosting efficiency and accelerating progress on challenging diseases.